IC
AUPH icon

Ikarian Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Ikarian Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-100,000
Closed -$1.45M – 176
2020
Q1 		$1.45M Buy
+100,000
New +$1.76M 0.11% 106

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Ikarian Capital's AUPH Position: Q2 2022 in Review

Ikarian Capital sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2022, closing a stake of 87,071 shares — an estimated $1.08M sold.

Ikarian Capital first reported a position in AUPH in Q4 2019 and held it in 5 quarters. The position peaked at $9.75M in Q4 2019. 199 funds tracked by Wall St. Rank hold AUPH as of Q2 2022.

  • Ikarian Capital reported no remaining Aurinia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 87,071 Aurinia Pharmaceuticals shares in Q2 2022, an estimated $1.08M.
  • Ikarian Capital first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • Ikarian Capital's Aurinia Pharmaceuticals position peaked at $9.75M in Q4 2019.
  • 199 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.